A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency

Last updated: September 22, 2022
Sponsor: Institute of Hematology & Blood Diseases Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Anemia

Aplastic Anemia

Treatment

N/A

Clinical Study ID

NCT05531279
IIT2021022-EC-1
  • Ages 18-70
  • All Genders

Study Summary

This study was a single-center,open-label,randomized,dose-exploring prospective study.Patients with granulocytotic aplastic anemia who received cytokine treatment with PEG-rhG-CSF or rhG-CSF were enrolled.Clinical demographic data,disease characteristics of aplastic anemia,clinical diagnosis and treatment,laboratory data and adverse events were collected to explore the dose and safety of PEG-rhG-CSF and rhG-CSF in patients with severe aplastic anemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18-70 years old, male or female, or weight≥50kg.
  2. Patients with severe or very severe aplastic anemia of absolute neutrophil value< 0.5×109/L
  3. ECOG score ≤ 2 points.
  4. Normal renal function.

Exclusion

Exclusion Criteria:

  1. Patients with clonal chromosomal abnormalities.
  2. Patients with previous malignant tumors.
  3. Patients with severe or uncontrolled infectious diseases and /or bleeding.
  4. Patients with AIDS or syphilis positive.
  5. Severe organ dysfunction.
  6. Patients used GM/G-CSF,PEG-rhG-CSF,interleukin-11 within 2 weeks before admission.
  7. Allergic to G-CSF or PEG-rhG-CSF related components.
  8. Participated in other clinical trials within 6 months.

Study Design

Total Participants: 45
Study Start date:
June 05, 2022
Estimated Completion Date:
January 05, 2026

Study Description

This study was a single-center,open-label,randomized,dose-exploring prospective study.Patients with granulocytotic aplastic anemia who received cytokine treatment with PEG-rhG-CSF or rhG-CSF were enrolled.Clinical demographic data,disease characteristics of aplastic anemia,clinical diagnosis and treatment,laboratory data and adverse events were collected to explore the dose and safety of PEG-rhG-CSF and rhG-CSF in patients with severe aplastic anemia.Research objectives: To explore the reasonable injection frequency of long-acting PEG-rhG-CSF in the adjuvant treatment of aplastic anemia patients with granulocytosis through a single center prospective clinical study.Disease classification of aplastic anemia: a total of 45 cases of SAA/VSAA with ANC<0.5×109/L were stratified and randomized into three groups according to the radio of 1:1:1(15 cases in each group).PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected;PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected;RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.Dose/protocol adjustment: after monitoring ANC>0.5×109/L,the drug was stopped,and then ANC<0.5×109/L was temporarily supplemented with one dose of the original group of drugs.

Connect with a study center

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin 300020
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.